Observational studyRheumatology international2020
Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.
Observational study in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Review
- The association of symptoms, pulmonary function test and computed tomography in interstitial lung disease at the onset of connective tissue disease: an observational study with artificial intelligence analysis of high-resolution computed tomography.Rheumatology international · 2025Observational
- Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review.Frontiers in medicine · 2025Review
- Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis.Archives of rheumatology · 2024Review
- The Spectrum of Extraglandular Manifestations in Primary Sjögren's Syndrome.Journal of personalized medicine · 2023Review
- Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease.Rheumatology international · 2023Review
- Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?International journal of molecular sciences · 2023Review
- Systemic Lupus Erythematosus and Lung Involvement: A Comprehensive Review.Journal of clinical medicine · 2022Review
- Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study.Journal of clinical medicine · 2022Article
- Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion.Frontiers in medicine · 2022Review
- Respiratory Manifestations in Systemic Lupus Erythematosus.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease.Drugs in context · 2021Review
- Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review.Journal of clinical medicine · 2020Article
- Article
- Immunomodulatory treatment of interstitial lung disease.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive connective tissue disease (CTD)-related lung disease is a challenging condition that requires lung transplantation in some patients. Treatment with rituximab may improve lung function. To evaluate the effect of rituximab in patients with progressive CTD-related lung disease who met criteria for inclusion in waiting list for a lung transplant. Retrospective study of patients with progressive CTD-related lung disease with criteria for lung transplant (FVC < 60% and/or DLCO < 40%) that started treatment with rituximab because of disease progression. Clinical variables, pulmonary function tests and chest computed tomography were used to monitor the effect of rituximab. The cohort included 18 patients; systemic sclerosis (7), rheumatoid arthritis (5), systemic lupus erythematosus (4), Sjögren syndrome (1) and antisynthetase syndrome (1). The radiologic patterns observed were: usual interstitial pneumonia (1), non-specific interstitial pneumonia (9), lymphoid interstitial pneumonia (1), emphysema-usual interstitial pneumonia (1), shrinking lung syndrome (3) and undetermined pattern (3). Over the previous year to rituximab initiation a decline in FVC (- 3.8%, p = 0.095) and DLCO (- 8.4%, p = 0.004) was observed. After 2 years of treatment, DLCO significantly improved (+ 12.4%, p < 0.001 at 1 year and + 15.3%, p = 0.001 at 2 years). Six patients (33.3%) presented adverse events related to rituximab. No patient required lung transplant or died during the study period. Rituximab is an effective treatment for patients with severe and progressive CTD-related lung disease, which allows to delay lung transplantation in some cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.